1. Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer
- Author
-
J. de Bono, Carmel Jo Pezaro, Roberta Ferraldeschi, and Vasilios Karavasilis
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Androgen receptor signaling pathway ,Antiandrogens ,General Biochemistry, Genetics and Molecular Biology ,chemistry.chemical_compound ,Prostate cancer ,Castration Resistance ,Internal medicine ,medicine ,Humans ,Enzalutamide ,Castration ,Androstenols ,business.industry ,Abiraterone acetate ,Prostatic Neoplasms ,Androgen Antagonists ,General Medicine ,medicine.disease ,Androgen receptor ,Treatment Outcome ,Endocrinology ,chemistry ,Androgens ,Androstenes ,Cancer biomarkers ,business - Abstract
Suppression of gonadal androgens by medical or surgical castration remains the mainstay of treatment for patients with advanced prostate cancer. However, the response to treatment is not durable, and transition to a “castration-resistant” state is invariable. Recent advances in our understanding of the androgen receptor signaling pathway have led to the development of therapeutic strategies to overcome castration resistance. This article reviews current concepts and challenges behind targeting continued androgen receptor signaling in castration-resistant prostate cancer and provides an overview of recently completed and ongoing clinical trials of novel hormonal agents, with a focus on abiraterone acetate and enzalutamide (MDV3100).
- Published
- 2013